Background: Phlebitis is an inflammatory process that is characterized by inflamed venous endothelial cells. Vesicant medications are found to be one of the causes of phlebitis, especially in pediatric patients.

Objective: To investigate the correlation between the use of vesicant medications and phlebitis incidence.

Material and methods: The study was descriptive observational conducted over the period of June-July 2022 in a pediatric ward. The inclusion criteria were male or female pediatric inpatients, aged 1 month-18 years, and receiving medication via intravenous infusion for >24 hours. The data obtained were then analyzed for correlations by using bivariate and multivariate analysis.

Results and conclusion: A total of 174 patients met the inclusion criteria; 27.6% experienced phlebitis, and 37.9% received vesicant medications. The most frequently used vesicant medications in the pediatric ward was gentamicin (74.24%). The use of vesicants and administration of >3 intravenous drugs showed statistically significant results associated with the incidence of phlebitis, with RR: 4.17 (P < 0.001; CI = 2.1-8.3) and RR = 2.6 (P = 0.012; CI = 1.2-5.5), respectively. The multivariate test results showed that the use of vesicants was a risk factor for phlebitis, with OR = 4.41 (P < 0.001; CI = 2.0-9.7). The use of vesicants is associated with the incidence of phlebitis in a pediatric inpatient ward.

Annisa L, Hanifah S, Setiani P. Correlation Between the Use of Vesicant Medications and The Incidence of Phlebitis in Pediatric Ward. J Pharm Bioallied Sci. 2024 Dec;16(Suppl 4):S4103-S4106. doi: 10.4103/jpbs.jpbs_1062_24. Epub 2024 Dec 27. PMID: 39926814; PMCID: PMC11805223.